Cosmos Health Inc. has secured a cumulative orderbook of over 25 million units through its wholly owned subsidiary Cana Laboratories S.A., positioning the contract manufacturing division to generate over $10 million in recurring annual profit at full capacity. The agreements span multiple partners and nine therapeutic categories, with contract terms extending up to 10 years, providing long-term cash flow visibility and reducing dependence on any single product or partner.

Cana operates a 54,000 sq. ft., EU-GMP-licensed, EMA-certified facility in Athens. The company has invested approximately $5.5 million in upgrading the facility, including the installation of a new ACG capsule-filling line, to expand its capabilities. The orderbook includes diverse formats such as vials, packs, bottles, capsules, and pessaries, covering central nervous system, musculoskeletal, dermatological, vitamin, anti-inflammatory, oncology-support, women’s health, antiseptic, and wellness categories.

Contract Manufacturing Orderbook

The following table details the key agreements secured by Cana Laboratories:

Strategic Impact

Cosmos Health views contract manufacturing as a high-margin, recurring-revenue segment central to its vertically integrated model. By leveraging its EU-licensed facility to serve third-party partners, the company aims to maximize utilization, spread fixed costs, and generate incremental revenue while maintaining control over the quality and supply of its own proprietary brands. With current agreements using only a portion of available capacity, the company continues to pursue additional contracts and evaluate further expansion.

Cosmos Health Inc. has entered the global beauty and personal care market, launching a premium, Korean-developed collagen-based skincare line in the United States. The move targets the $163 billion global skincare market, which is projected to reach approximately $203 billion by 2033, according to Grand View Research. This strategic expansion aims to diversify the company's portfolio into higher-margin, high-growth categories.

Sales of the new brand have been live for over a month in the U.S., utilizing a direct-to-consumer model designed for global scale. Cosmos Health plans to roll out a series of products, pursuing a multi-brand strategy to deepen its presence in the skincare sector. The company stated that premium skincare is among the fastest-growing segments, driven by rising consumer demand for science-backed formulations.

Greg Siokas, CEO of Cosmos Health, emphasized that entering the beauty market is a natural extension of the company's strategy. He highlighted that the direct-to-consumer model and planned multi-brand portfolio are expected to contribute significantly to future growth. The launch marks a key step in the company's diversification toward more lucrative end markets.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company owns proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, and bio-bebe®. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, and cosmetics within the European Union.

The company distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Cosmos Health has also established R&D partnerships targeting major health disorders and entered the telehealth space via the acquisition of ZipDoctor, Inc. Its global distribution platform includes offices and distribution centers in Greece and the UK.